The STS/ASTRO/ASCO Recommendations on the Care of Patients with Localized Esophageal Cancers

Over the last decade, with the implementation of multimodal therapy, consisting of surgery, chemotherapy and radiation, otherwise known as trimodality therapy, outcomes for patients with esophageal cancer have improved, from a survival rate of 5% in 1970 to the current survival rate of 22% (2,3) for all stages combined.(1) For esophageal cancers that are localized or regional, the survival rates are 49% and 28% respectively.(2) Although there is agreement in what the treatment entails, there is wide variation in its implementation, based on physician bias, the broad range of surgical and medical literature, and guidelines by individual specialty societies.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Editorial Source Type: research